
Takeda looks toward 'inflection point' as it eyes new launches to shake off Vyvanse generic impacts
This time last year, Takeda was scrambling to accommodate for rapidly sinking profits from the hasty decline of ADHD mainstay Vyvanse with a 140 billion Japanese yen ($899 million) restructuring campaign. Now, things are looking up for the Japanese …